PharmaCyte Biotech
PharmaCyte Biotech is a clinical-stage public biotechnology company developing cellular therapies for cancer and diabetes using its proprietary Cell-in-a-Box encapsulation platform, with no commercialized products and revenue dependent on future FDA approval.
- Company typePrivate
- Founded1996
- HeadquartersLaguna Hills, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What PharmaCyte Biotech does
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company headquartered in Las Vegas, Nevada (corporate address 3960 Howard Hughes Parkway, Suite 500) and listed on Nasdaq under ticker PMCB. Founded in 1996, the company employs between 1 and 10 people and is focused on developing cellular therapies for cancer and diabetes using its proprietary Cell-in-a-Box technology platform, which encapsulates and delivers therapeutic cells.
The Cell-in-a-Box platform is the company's single core product asset and underpins all clinical development programs. PharmaCyte is pursuing indications including malignant ascites (a complication of advanced-stage cancers) and diabetes, with the encapsulation architecture positioned as a novel delivery method for targeted cellular therapies. No commercialized products exist, and pricing is therefore not applicable; the company operates in clinical development and prepares for eventual FDA approval pathways rather than direct product sales.
The business model is pre-revenue and dependent on equity capital markets. The company has raised capital through public offerings (notably a $15M offering in August 2021 led by H.C. Wainwright raising ~$13.6M net, and a $7M raise in August 2025 led by existing investors). In 2022, the company underwent governance changes following a cooperation agreement with Iroquois Capital that installed five new independent directors and established a Business Review Committee to evaluate strategic alternatives for shareholder value. Patient and provider engagement is limited to clinical trials rather than commercial distribution.
PharmaCyte Biotech firmographics
Firmographics- Name
- PharmaCyte Biotech
- Legal name
- PharmaCyte Biotech, Inc.
- Website
- https://pharmacytebiotech.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- PharmaCyte Biotech is a clinical-stage public biotechnology company developing cellular therapies for cancer and diabetes using its proprietary Cell-in-a-Box encapsulation platform, with no commercialized products and revenue dependent on future FDA approval.
- Ownership category
- akta.pro rank
PharmaCyte Biotech industry classification
Industry- Product category
- Biotechnology Cellular Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)
- akta.pro secondary industry
- Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)
Keywords
Where PharmaCyte Biotech is headquartered
LocationHeadquarters
- HQ city
- Laguna Hills
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
PharmaCyte Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Marketing channels5 records
PharmaCyte Biotech product offering
Product offeringCore offering
PharmaCyte Biotech is a clinical-stage biotechnology company developing cellular therapies for cancer (notably advanced-stage malignancies with malignant ascites) and diabetes using its proprietary Cell-in-a-Box encapsulation platform. The technology encapsulates therapeutic cells in a cellulose-based matrix to enable targeted delivery of biologically active treatments. The company has no commercially approved products and is focused on advancing its pipeline through clinical development and regulatory pathways.
Product overview
PharmaCyte Biotech is a clinical-stage biotechnology company developing a single unified product platform: the Cell-in-a-Box technology. This core technology platform is designed to encapsulate and deliver therapeutic cells for the treatment of cancer and diabetes. The company's product pipeline centers on leveraging this cellular delivery system to create novel therapeutic approaches for malignant ascites (a complication of advanced-stage cancers) and diabetes treatment. The Cell-in-a-Box platform serves as the foundational technology underpinning all of PharmaCyte's clinical development programs.
Differentiator
Problem solved
Functional benefit
Companies that use PharmaCyte Biotech
Customer profileSegments1 record
Ideal customer profiles2 records
PharmaCyte Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
PharmaCyte Biotech partnerships and signals
Strategic signalScale indicators2 records
Recent moves4 records
Expansion highlights4 records
PharmaCyte Biotech competitors and assessment
Company assessmentDirect peers
- Iovance Biotherapeutics: Clinical-stage cell therapy company developing tumor-infiltrating lymphocyte (TIL) therapies for advanced cancers; the most direct comparable to PharmaCyte's cell-therapy approach in oncology, with a similar focus on hard-to-treat advanced-stage solid tumors.
- Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered T-cell therapies for solid tumors; directly comparable to PharmaCyte as a small-cap, clinical-stage cell therapy company targeting oncology indications.
- Fate Therapeutics: Clinical-stage cell therapy company with a platform approach to develop off-the-shelf NK and T-cell cancer therapies; comparable to PharmaCyte as a platform-based cell therapy developer targeting multiple oncology indications.
- bluebird bio: Clinical-stage gene and cell therapy company with multiple programs in oncology and rare diseases; directly comparable as a small-cap, clinical-stage developer of cellular therapies, though now focused on gene therapy.
- Allogene Therapeutics: Clinical-stage allogeneic CAR T-cell therapy company for cancer; directly comparable to PharmaCyte as a clinical-stage cell therapy developer focused on oncology with a platform-based approach.
- Cellectis: Clinical-stage gene and cell therapy company developing allogeneic CAR T-cell therapies for cancer; directly comparable as a clinical-stage cell therapy platform company in oncology.
- ViaCyte: Clinical-stage cell therapy company developing encapsulated stem cell-derived therapies for diabetes; the most direct peer to PharmaCyte's diabetes program, sharing the encapsulated cell-therapy approach.
Emerging players
- Sigilon Therapeutics: Clinical-stage cell therapy company developing encapsulated cell therapies for chronic diseases including diabetes; closely comparable to PharmaCyte's Cell-in-a-Box encapsulation concept in diabetes and adjacent applications.
- Nkarta: Clinical-stage cell therapy company developing engineered NK cell therapies for cancer; comparable to PharmaCyte as a small-cap clinical-stage cell therapy developer focused on oncology applications.
- Tessa Therapeutics: Clinical-stage cell therapy company developing autologous and allogeneic T-cell therapies for solid tumors; comparable to PharmaCyte as a clinical-stage cell therapy developer targeting oncology indications.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
PharmaCyte Biotech social profiles
Digital presencePharmaCyte Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
PharmaCyte Biotech leadership team
Management profileNumber of profiles
Profiles5 records
PharmaCyte Biotech funding detail
Funding detailFunding overview
Funding rounds5 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PharmaCyte Biotech M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PharmaCyte Biotech
What does PharmaCyte Biotech do?
PharmaCyte Biotech is a clinical-stage biotechnology company developing cellular therapies for cancer (notably advanced-stage malignancies with malignant ascites) and diabetes using its proprietary Cell-in-a-Box encapsulation platform. The technology encapsulates therapeutic cells in a cellulose-based matrix to enable targeted delivery of biologically active treatments. The company has no commercially approved products and is focused on advancing its pipeline through clinical development and regulatory pathways.
Is PharmaCyte Biotech a public or private company?
PharmaCyte Biotech is a private company. It is classified as public and is currently operating.
When was PharmaCyte Biotech founded?
PharmaCyte Biotech was founded in 1996. It employs 1 to 10 people.
Where is PharmaCyte Biotech based?
PharmaCyte Biotech is headquartered in Laguna Hills, United States, in the North America region.
Who are PharmaCyte Biotech's main competitors?
Direct peers on record are Iovance Biotherapeutics, Adaptimmune Therapeutics, Fate Therapeutics, bluebird bio, Allogene Therapeutics, Cellectis and ViaCyte. Emerging players are Sigilon Therapeutics, Nkarta and Tessa Therapeutics.
Does PharmaCyte Biotech have an API?
No public API is recorded for PharmaCyte Biotech.
What industry is PharmaCyte Biotech in?
PharmaCyte Biotech's product category is Biotechnology Cellular Therapy. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish), with a secondary code of HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic). Its NAICS code is 325414 and its SIC code is 2836.